Invivyd, Inc. (IVVD) 10-Year Financial Performance & Capital Metrics

IVVD • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutAdagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.Show more

Revenue $25M
EBITDA -$174M +17.5%
Net Income -$170M +14.5%
EPS (Diluted) -1.43 +21.0%
Gross Margin 93.63%
EBITDA Margin -684.54%
Operating Margin -696.8%
Net Margin -669.42%
ROE -138.71% -86.2%
ROIC -
Debt/Equity 0.02 +58.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM332.71%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.41%

EPS CAGR

10Y-

5Y-

3Y-

TTM76.02%

ROCE

10Y Avg-90.56%

5Y Avg-90.56%

3Y Avg-92.31%

Latest-143.55%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.35B	18.28	22.57	65.15%	42.87%	48.57%	2.53%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	86.21M	2.90	-0.23			-49.37%		0.24
INOInovio Pharmaceuticals, Inc.	112.67M	1.64	-0.42	-73.83%	-592.82%	-115.42%		0.17
ALGSAligos Therapeutics, Inc.	48.45M	9.05	-0.43	-74.6%	-32.68%	-120.37%
BRNSBarinthus Biotherapeutics plc	30.83M	0.76	-0.49	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.99M	1.16	-0.67			-126.11%		0.19
KLRSKalaris Therapeutics Inc	172.81M	9.24	-0.79			-170.84%

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	25.38M
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	1.62M
COGS % of Revenue	-	-	-	-	0.06%
Gross Profit+	0	0	0	0	23.77M
Gross Margin %	-	-	-	-	0.94%
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	111.99M	226.91M	248.03M	212.76M	200.64M
OpEx % of Revenue	-	-	-	-	7.9%
Selling, General & Admin	0	36.52M	47.04M	49.13M	63.39M
SG&A % of Revenue	-	-	-	-	2.5%
Research & Development	106.49M	182.89M	179.21M	158.66M	137.25M
R&D % of Revenue	-	-	-	-	5.41%
Other Operating Expenses	5.5M	7.5M	21.77M	4.97M	0
Operating Income+	-111.99M	-226.91M	-248.03M	-212.76M	-176.88M
Operating Margin %	-	-	-	-	-6.97%
Operating Income Growth %	-	-1.03%	-0.09%	0.14%	0.17%
EBITDA+	-68.79M	-226.91M	-247.57M	-210.73M	-173.76M
EBITDA Margin %	-	-	-	-	-6.85%
EBITDA Growth %	-	-2.3%	-0.09%	0.15%	0.18%
D&A (Non-Cash Add-back)	43.2M	1K	462K	2.03M	3.11M
EBIT	-43.2M	-219.41M	-226.26M	-207.78M	-176.88M
Net Interest Income+	8K	0	-36.37M	0	6.95M
Interest Income	8K	0	6.71M	0	6.95M
Interest Expense	0	0	43.08M	0	0
Other Income/Expense	13.71K	118K	6.71M	14.12M	6.95M
Pretax Income+	-111.98M	-226.79M	-241.32M	-198.64M	-169.93M
Pretax Margin %	-	-	-	-	-6.69%
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-111.98M	-226.79M	-241.32M	-198.64M	-169.93M
Net Margin %	-	-	-	-	-6.69%
Net Income Growth %	-	-1.03%	-0.06%	0.18%	0.14%
Net Income (Continuing)	-111.98M	-226.79M	-241.32M	-198.64M	-169.93M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.59	-2.11	-2.17	-1.81	-1.43
EPS Growth %	-	-2.58%	-0.03%	0.17%	0.21%
EPS (Basic)	-0.59	-2.11	-2.17	-1.81	-1.43
Diluted Shares Outstanding	111.25M	110.78M	108.27M	109.53M	118.56M
Basic Shares Outstanding	111.25M	110.78M	108.27M	109.53M	118.56M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	117.38M	616.71M	376.92M	224.88M	100.68M
Cash & Short-Term Investments	114.99M	591.42M	371.99M	200.64M	69.35M
Cash Only	114.99M	542.22M	92.08M	200.64M	69.35M
Short-Term Investments	0	49.19M	279.92M	0	0
Accounts Receivable	0	229K	377K	933K	11.17M
Days Sales Outstanding	-	-	-	-	160.6
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	0	0	0
Total Non-Current Assets+	0	3.38M	6.25M	4.3M	28.83M
Property, Plant & Equipment	0	83K	6.06M	4.13M	2.89M
Fixed Asset Turnover	-	-	-	-	8.77x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	3.3M	191K	175K	25.94M
Total Assets+	117.38M	620.09M	383.17M	229.18M	129.51M
Asset Turnover	-	-	-	-	0.20x
Asset Growth %	-	4.28%	-0.38%	-0.4%	-0.43%
Total Current Liabilities+	13.07M	62.06M	25.03M	50.29M	61.98M
Accounts Payable	8.15M	5.78M	1.52M	7.95M	10.45M
Days Payables Outstanding	-	-	-	-	2.36K
Short-Term Debt	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	794K	4.95M	6.03M	10.79M	3.94M
Current Ratio	8.98x	9.94x	15.06x	4.47x	1.62x
Quick Ratio	8.98x	9.94x	15.06x	4.47x	1.62x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	169.56M	12K	2.17M	1.42M	0
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	2.17M	722K	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	169.56M	12K	1K	700K	0
Total Liabilities	182.63M	62.07M	27.2M	51.71M	61.98M
Total Debt+	0	0	3.72M	2.17M	1.3M
Net Debt	-114.99M	-542.22M	-88.35M	-198.48M	-68.05M
Debt / Equity	-	-	0.01x	0.01x	0.02x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-5.76x	-	-
Total Equity+	-65.25M	558.02M	355.97M	177.47M	67.54M
Equity Growth %	-	9.55%	-0.36%	-0.5%	-0.62%
Book Value per Share	-0.59	5.04	3.29	1.62	0.57
Total Shareholders' Equity	-65.25M	558.02M	355.97M	177.47M	67.54M
Common Stock	1K	11K	11K	11K	12K
Retained Earnings	-65.32M	-292.11M	-533.43M	-732.07M	-901.99M
Treasury Stock	-85K	0	0	0	0
Accumulated OCI	0	-8K	-272K	-13K	-5K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-14.57M	-184.74M	-219.99M	-173.16M	-170.49M
Operating CF Margin %	-	-	-	-	-6.72%
Operating CF Growth %	-	-11.68%	-0.19%	0.21%	0.02%
Net Income	-65.32M	-226.79M	-241.32M	-198.64M	-169.93M
Depreciation & Amortization	0	1K	462K	2.03M	3.11M
Stock-Based Compensation	0	17.76M	21.65M	18.68M	19.79M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	40.07M	1.5M	15.35M	-1.12M	0
Working Capital Changes	10.68M	22.79M	-16.13M	5.89M	-23.47M
Change in Receivables	0	0	0	0	-10.91M
Change in Inventory	0	0	0	0	-24.89M
Change in Payables	0	-2.37M	-4.3M	6.47M	2.42M
Cash from Investing+	0	-50.71M	-230.67M	280.68M	-140K
Capital Expenditures	0	-84K	-1.71M	-615K	-140K
CapEx % of Revenue	-	-	-	-	0.01%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	129.56M	662.68M	506K	1.04M	39.33M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	-3.38M	510K	1.05M	46K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-14.57M	-184.82M	-221.69M	-173.78M	-170.63M
FCF Margin %	-	-	-	-	-6.72%
FCF Growth %	-	-11.68%	-0.2%	0.22%	0.02%
FCF per Share	-0.13	-1.67	-2.05	-1.59	-1.44
FCF Conversion (FCF/Net Income)	0.13x	0.81x	0.91x	0.87x	1.00x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-92.05%	-52.81%	-74.48%	-138.71%
Return on Invested Capital (ROIC)	-	-	-131.27%	-129.41%	-
Gross Margin	-	-	-	-	93.63%
Net Margin	-	-	-	-	-669.42%
Debt / Equity	-	-	0.01x	0.01x	0.02x
Interest Coverage	-	-	-5.76x	-	-
FCF Conversion	0.13x	0.81x	0.91x	0.87x	1.00x

Revenue by Segment

	2024
Product	25.38M
Product Growth	-

Frequently Asked Questions

Growth & Financials

Invivyd, Inc. (IVVD) reported $50.0M in revenue for fiscal year 2024.

Invivyd, Inc. (IVVD) grew revenue by 0.0% over the past year. Growth has been modest.

Invivyd, Inc. (IVVD) reported a net loss of $59.9M for fiscal year 2024.

Dividend & Returns

Invivyd, Inc. (IVVD) has a return on equity (ROE) of -138.7%. Negative ROE indicates the company is unprofitable.

Invivyd, Inc. (IVVD) had negative free cash flow of $80.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener